China News Service, Beijing, March 19 (Wei Wei) Zhao Qiang (pseudonym), a 35-year-old from Guizhou, saw snow in Beijing for the first time.

"My wish has finally come true!" What made him even more excited was that on the 22nd National Liver Love Day, he was discharged from the hospital two weeks after undergoing anatomical liver resection.

　　Zhao Qiang is the first patient with primary intermediate-advanced liver cancer treated with yttrium [90Y] resin microsphere injection in China.

On March 4, he underwent anatomical liver resection at Tsinghua Chang Gung Hospital in Beijing.

On March 18, he recovered well and was discharged from the hospital, and the "yttrium" key restarted the freshman.

　　As the chief surgeon of the operation, Dong Jiahong, academician of the Chinese Academy of Engineering and president of Beijing Tsinghua Chang Gung Memorial Hospital, said: "After discussion by experts in multidisciplinary diagnosis and treatment (MDT), it is agreed that his liver tumor has been clinically cured, and regular follow-up after discharge is sufficient. No adjuvant therapy is required."

　　Zhang Lin, deputy chief physician of the Department of Hepatobiliary Intervention at Tsinghua Chang Gung Hospital in Beijing, said that in June last year, the patient was diagnosed with primary liver cancer (CNLC stage IIIa), which no longer met the criteria for liver transplantation. Routine surgical resection is also not possible.

After several rounds of discussions, overseas experts and domestic MDT experts believe that the treatment of this patient with yttrium [90Y] resin microspheres is the best choice.

　　Yttrium[90Y] is a high-energy pure beta radioisotope, and yttrium[90Y] resin microspheres are composed of biocompatible resin microspheres containing yttrium[90Y].

In 2002, yttrium [90Y] resin microspheres were approved by the U.S. Food and Drug Administration (FDA), and more than 100,000 people have been treated in more than 50 countries and regions.

　　In September last year, Zhao Qiang performed a precision interventional operation of licensed yttrium [90Y] microsphere injection in Hainan.

Zhang Lin said, "The entire surgical procedure was done beautifully. The microcatheter was precisely inserted into the target blood vessel of the patient's liver tumor, and the yttrium [90Y] resin microspheres were successfully injected into the tumor blood vessel."

　　What is even more gratifying is that the results of the re-examination in December showed that the patient's liver tumor shrunk significantly compared to preoperatively, from 10.81 cm to 1.8 cm. 180446 ng/mL decreased to 1469 ng/mL.

"In January of this year, when the patient was reexamined, the active tumor lesions were completely regressed by imaging, and the AFP was reduced to 335 ng/mL." Zhang Lin said.

In other words, the patient is eligible for downstaging surgery.

　　When talking about the operation, Academician Dong Jiahong said that the team adopted a technical solution of precise liver resection, which achieved complete removal of lesions while maximizing the preservation of healthy liver parenchyma, and effectively controlled bleeding.

On the other hand, the success of this operation is also inseparable from MDT.

　　"After the patient was diagnosed with primary liver cancer last year, the Beijing Tsinghua Chang Gung Memorial Hospital team has been working closely with the Southwest Hospital of the Army Military Medical University, Hainan Cancer Hospital, Boao Super Hospital and overseas experts and professors from various disciplines where the patient first visited. The patient's condition has held several online and offline MDT discussions to help the patient formulate the best treatment plan," he said.

　　More importantly, experts have seen the role of yttrium [90Y] microspheres as a local treatment for advanced liver cancer.

　　"Over the past 40 years, the treatment of liver cancer in our country has been at the forefront of the world in many fields, but in the field of internal radiation therapy, there is a lack of a method such as yttrium [90Y] internal radiation therapy." Academician Dong Jiahong said.

　　According to reports, most patients with liver cancer are in the middle and advanced stages when they are discovered, and most patients cannot be surgically removed, and the recurrence rate within 5 years is high.

Interventional therapy has become a common non-curative therapy for these patients.

Yttrium [90Y] microsphere injection precision interventional radiation therapy combines interventional and precision internal radiation therapy.

　　On February 9 this year, the State Drug Administration of China officially approved the launch of yttrium yttrium [90Y] microsphere injection.

Yttrium [90Y] Microsphere Injection is developed and produced by Sirtex Medical Pty Ltd (Sirtex), an associate company of Grand Pharmaceuticals Group, the listed entity of Grand Pharmaceuticals (China) Co., Ltd., and many tertiary hospitals in China have the conditions for use or are actively preparing for it.

　　"This will enable a large number of patients with advanced liver cancer to obtain more effective treatment, which can improve their cure rate and prolong their overall survival." Academician Dong Jiahong said that liver cancer treatment has entered an era of diversification, and it is hoped that more patients will benefit from it.

(over)